Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Xencor to Present at Upcoming Investor Conferences

PR Newswire May 17, 2016

Xencor Reports First Quarter 2016 Financial Results

PR Newswire May 2, 2016

Xencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016

PR Newswire April 25, 2016

Xencor Reports Fourth Quarter and Full Year 2015 Financial Results

PR Newswire March 7, 2016

Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus

PR Newswire March 7, 2016

Xencor to Present at Cowen and Company 36th Annual Health Care Conference

PR Newswire March 2, 2016

Xencor to Host Fourth Quarter and Full Year 2015 Financial Results Webcast and Conference Call on March 7, 2016

PR Newswire February 29, 2016

Xencor to Present at Two Upcoming Conferences in February

PR Newswire February 3, 2016

Emergent Technologies Portfolio Company Enters into License Agreement with Xencor

Business Wire January 12, 2016

Xencor Announces Change to Board of Directors

PR Newswire January 11, 2016

National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology

PR Newswire January 7, 2016

Equities Lead Investor Sentiment - Research Reports on TriNet Group, Xencor, Keryx Biopharmaceuticals and TeleCommunication Systems

Accesswire December 11, 2015

Xencor to Present at Two Upcoming Conferences in December

PR Newswire November 24, 2015

Xencor Presents Data on XmAb5871 Program at American College of Rheumatology (ACR) 2015 Annual Meeting

PR Newswire November 9, 2015

Preclinical Data of Xencor's XmAb Bispecific Technology to be Presented at Upcoming ASH Annual Meeting

PR Newswire November 5, 2015

Xencor to Present at Credit Suisse 24th Annual Healthcare Conference

PR Newswire November 4, 2015

Xencor Reports Third Quarter 2015 Financial Results and Pipeline Update

PR Newswire November 3, 2015

Xencor to Host Third Quarter 2015 Financial Results Webcast and Conference Call on November 3, 2015

PR Newswire October 27, 2015

Xencor to Present at Leerink Partners Inaugural Immuno-Oncology Roundtable

PR Newswire September 24, 2015

Xencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate Using XmAb® Cytotoxic Fc Domain

PR Newswire September 24, 2015